Skip to main content
Aller à la page d’accueil de la Commission européenne (s’ouvre dans une nouvelle fenêtre)
français fr
CORDIS - Résultats de la recherche de l’UE
CORDIS
Contenu archivé le 2024-06-18

Highly efficient new generation synthetic RNA-replicon based vaccine

Objectif

The project seeks to create a novel, efficacious vaccine against influenza virus; a new type of synthetic vaccine readily adaptable to meet whichever influenza virus subtype may arise. A new generation of RNA-replicon technology will be employed combined with nanoparticles and innovative adjuvants for targeting of dendritic cells and efficient antigen expression. The consortium comprises two SMEs and two academic institutions each having unique and patented expertise such as replicon technology, nanoparticle technology, adjuvant chemistry, and surface modification chemistry to attach targeting moieties. As a highly interdisciplinary project, extensive exchange of knowledge between the project partners will be required in particular between product focused SMEs (nanoparticles, adjuvants) and technology excellence of academic institutions (replicon technology, surface modification chemistry).

Champ scientifique (EuroSciVoc)

Programme(s)

Thème(s)

Appel à propositions

FP7-PEOPLE-2009-IAPP
Voir d’autres projets de cet appel

Régime de financement

MC-IAPP - Industry-Academia Partnerships and Pathways (IAPP)

Coordinateur

THE UNIVERSITY OF MANCHESTER
Contribution de l’UE
€ 799 522,00
Adresse
OXFORD ROAD
M13 9PL Manchester
Royaume-Uni
Région
North West (England) Greater Manchester Manchester
Type d’activité
Higher or Secondary Education Establishments
Liens
Coût total
Aucune donnée

Participants (3)